Sirolimus coated tablet and preparation method thereof

The solubility and bioavailability of sirolimus are improved through the multi-layer coating process, which solves the problems of poor water solubility and rapid metabolism, and achieves the improvement of stability and production costs.

CN119055609APending Publication Date: 2024-12-03江苏济茗医药有限公司
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410594085.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-14
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The poor water solubility and ease of metabolism of sirolimus lead to low oral bioavailability, and the dissolution rate of traditional preparations is unpredictable, and there is a lack of convenient solid oral preparations.

Method used

Using a multi-layer coating process, including placebo tablet core, sealing layer coating, active filler coating and coloring coating, through diluents, adhesives, lubricants, plasticizers, stabilizers, fillers, anti- The oxidant and other ingredients can improve the solubility and stability of sirolimus, and prepare sirolimus coated tablets.

Benefits of technology

It improves the solubility and oral bioavailability of sirolimus in the gastrointestinal tract, reduces production costs and equipment requirements, extends stability, reduces the growth of unknown degraded impurities, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055609A_ABST
    Figure CN119055609A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of medicine preparation, and relates to a sirolimus coated tablet and a preparation method thereof.The sirolimus coated tablet sequentially comprises a placebo tablet core, a sealing layer coating, an active filler coating and a coloring coating from inside to outside, and the placebo tablet core comprises a diluent, an adhesive and a lubricant; the sealing layer coating comprises a plasticizer, a coating agent and a solvent; the active filler coating comprises sirolimus, a stabilizer, a solvent, a filler, an adhesive and an antioxidant; the coloring coating comprises a filling agent, a coloring agent, an adhesive and a solvent. According to the preparation method disclosed by the invention, the solubility of the sirolimus in gastrointestinal tracts can be improved, so that the oral bioavailability of the sirolimus is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medicine preparation and relates to a sirolimus coated tablet and a preparation method thereof. Background Art

[0002] The process of spraying a relatively stable polymer coating evenly on the surface of the tablet core by spraying to form a plastic film layer several microns thick to achieve a certain expected effect is called film coating. The principle is that the tablet core keeps moving in a complex trajectory in a clean, closed, rotating drum, and the coating excipients are automatically sprayed according to the optimized process parameters. At the same time, the set hot air is supplied under a controllable negative pressure state. The hot air is discharged through the bottom of the tablet core layer, so that the coating medium sprayed on the surface of the tablet core is quickly and evenly dried, thereby quickly forming a solid, dense, flat and smooth surface film on the surface of the tablet core.

[0003] In the formulation process design of drug preparations, coating is generally considered for the following reasons: 1. Provide drug stability to avoid light and moisture; 2. Increase patient compliance and cover the unpleasant taste of drugs; 3. Separate ingredients that affect each other / incompatible; 4. Improve drug recognition and increase safety; 5. Remove dust and improve fluidity; 6. Improve aesthetics and cover the poor base color of the tablet core; 7. Change the release of drugs, such as enteric coating or sustained-release coating. Film coating powder is composed of four parts: film-forming agent, plasticizer, filler and colorant.

[0004] Sirolimus is a third-generation immunosuppressant, which is commonly used in clinical practice to inhibit immune rejection reactions after liver, kidney and other organ transplants. It belongs to Class II drugs in the biopharmaceutics classification, has extremely low solubility in water, and good permeability. Sirolimus has high pharmacological activity, but due to its poor water solubility and easy extensive metabolism by CYP3A4 isozymes in the intestinal wall and liver, its oral bioavailability is low, which is one of the important defects in the clinical use of sirolimus. When ordinary sirolimus preparations are prepared using traditional excipients and processes, the dissolution rate is difficult to predict after oral administration to the human body, and the in vivo variability is high. At present, only a small amount of sirolimus preparations can be used by the human body, and these include liquid oral preparations and intravenous injections. Convenient and takeable solid preparations of sirolimus are urgently needed to be developed. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides a sirolimus drug-coated tablet and a preparation method thereof. The preparation method of the present invention can improve the solubility of sirolimus in the gastrointestinal tract, thereby improving its oral bioavailability.

[0006] The technical solution provided by the present invention is as follows: A sirolimus coated tablet, which comprises, from the inside to the outside, a placebo core, a sealing layer coating, an active filler coating and a coloring coating, wherein the placebo core comprises a diluent, an adhesive and a lubricant; the sealing layer coating comprises a plasticizer, a coating agent and a solvent; the active filler coating comprises sirolimus, a stabilizer, a solvent, a filler, an adhesive and an antioxidant; and the coloring coating comprises a filler, a colorant, an adhesive and a solvent.

[0007] Furthermore, the mass ratio of the placebo core, the seal layer coating, the active filler coating and the coloring coating is 5-6:1:4-6:1, preferably 5.8:1:5.2:1.

[0008] Furthermore, the diluent is one or more of starch, dextrin, lactose, and microcrystalline cellulose; the binder is one or more of povidone K30 / K90, hypromellose, and polyethylene glycol; the lubricant is one or more of magnesium stearate, talc, and silicon dioxide; In the sealing layer coating, the plasticizer is one or more of citrate, phthalate, glycerin, and polyethylene glycol; the coating agent is one or more of resin, gum arabic, shellac, and calcium sulfate; and the solvent is alcohol; In the active filler coating, the stabilizer is one or more of polyethylene glycol, castor oil, poloxamer, and Tween; the solvent is water; the filler is one or more of sucrose, corn starch, lactose, and microcrystalline cellulose; the binder is one or more of povidone K30 / K90 and hydroxypropyl methylcellulose; the antioxidant is one of sodium sulfite, vitamin C / E, sodium thiosulfate, and butylated p-hydroxyanisole; In the colored coating, the filler is one or more of sucrose, corn starch, lactose, and microcrystalline cellulose; the colorant is one or more of titanium dioxide and yellow / brown iron oxide; the binder is one or more of povidone K30 / K90 and hypromellose; and the solvent is water; The present invention also provides a method for preparing the above-mentioned sirolimus coated tablets, the method comprising the following steps: mixing a diluent, a binder and a lubricant and then tableting to obtain a placebo tablet core; adding a coating agent to a hot alcohol solution in which a plasticizer is dissolved, stirring evenly to obtain a sealing layer coating solution, applying a sealing layer coating to the placebo tablet core and drying to obtain a sealed coated tablet; After the stabilizer and the solvent are uniformly mixed, sirolimus is added, and the sirolimus slurry is obtained after stirring, and the sirolimus slurry is pumped in a circulation manner and passed through a high-pressure homogenizer and a circulation chamber to obtain a sirolimus solid dispersion; purified water is first added to the sirolimus solid dispersion, and an antioxidant, a filler and a binder are added while stirring to obtain an active filler coating liquid, and the active filler coating liquid is sprayed on the sealed coated tablets to obtain active filler coated tablets; The filler, colorant, binder and solvent are mixed uniformly to obtain a color coating liquid, and the color coating liquid is sprayed on the active filler coated tablet to obtain sirolimus coated tablets.

[0009] Furthermore, the particle size distribution mean of the sirolimus solid dispersion is controlled to be less than 400 nm.

[0010] Further, the placebo tablet cores were seal coated with a seal coat and dried for at least 12 hours at a drying temperature of 25±2°C.

[0011] Furthermore, the temperature of the alcohol solution is 40-50°C.

[0012] Furthermore, in the sirolimus solid dispersion, the concentration of sirolimus is less than 40 mg / g.

[0013] Furthermore, the concentration of the active filler coating solution is less than 200 mg / g.

[0014] Furthermore, the weight gain of the active filler coated tablets relative to the placebo tablet cores is 80-110%. Beneficial Effects

[0015] Sirolimus has low solubility. The raw material is prepared into a solid dispersion form and then mixed with a filler, a binder and an antioxidant to form an active filler coating solution, so that the tablet can release the active ingredient smoothly, thereby solving the problem of sirolimus having a narrow therapeutic window and toxic effects easily caused by drug concentration in the body. In the process of preparing the solid dispersion, the raw material can be sheared at the same time to reduce the particle size of the raw material and increase the solubility of the raw material. The present invention uses purified water as a solid dispersion solvent to replace an organic solvent, thereby greatly reducing production costs and equipment requirements.

[0016] The present invention prepares the sirolimus raw material into a solid dispersion, and then uniformly sprays it on a placebo tablet core coated with a sealing layer by a coating process. The solid dispersion preparation has no requirements on the initial particle size of the raw material drug, and the raw material particle size requirement is relaxed from the stringent 400nm or less to 20um or less, which solves the problem of raw material particle size control and greatly reduces the cost of raw material particle size processing; the sealing layer coating step is used to prevent the quality change of the drug during the stability placement process, so that the moisture growth of the tablets under accelerated three-month conditions is reduced from 2.1% to 0.2%, and the growth of a single unknown degradation impurity is reduced from 0.124% to 0.028%; the coating solution is prepared with water as the solvent, and no organic solvent is needed, which reduces the production cost and equipment requirements and is suitable for industrial scale-up production. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 These are the curves of reference and homemade preparations in dissolution medium. DETAILED DESCRIPTION

[0018] A sirolimus coated tablet, wherein the coated tablet is prepared by a multi-layer coating process, and comprises, from the inside to the outside, a placebo tablet core, a sealing layer coating, an active filler coating, and a coloring coating, wherein the mass ratio of the placebo tablet core, the sealing layer coating, the active filler coating, and the coloring coating is 5.8:1:5.2:1; adding the sealing layer coating can protect the placebo tablet core and reduce the formation rate of unknown degradation impurities during the stability placement process; The active filler coating includes a bulk drug dispersion, a filler, a binder and an antioxidant, wherein the filler can be one or more of sucrose, corn starch, mannitol, lactose and microcrystalline cellulose; the binder can be one or more of povidone K30 / K90, hydroxypropyl methylcellulose and sodium carboxymethyl cellulose; the antioxidant can be one or more of sodium sulfite, vitamin C / E, sodium thiosulfate and butylated p-hydroxyanisole; the filler in the coloring coating can be one or more of sucrose, corn starch, lactose and microcrystalline cellulose; the colorant can be one or more of titanium dioxide and yellow / brown iron oxide; the binder can be one or more of povidone K30 / K90 and hydroxypropyl methylcellulose; Example 1

[0019] Placebo core tablet + active filler coating + color coating formula

[0020] The active ingredient is sirolimus; The diluent in the placebo tablet core may be one or more of starch, dextrin, lactose, and microcrystalline cellulose; the binder may be one or more of povidone K30 / K90, hypromellose, and polyethylene glycol; the lubricant may be one or more of magnesium stearate, talc, and silicon dioxide; The stabilizer in the active filler can be one or more of polyethylene glycol, castor oil, poloxamer, and Tween; the filler can be one or more of sucrose, corn starch, lactose, and microcrystalline cellulose; the binder can be one or more of povidone K30 / K90 and hydroxypropyl methylcellulose; the antioxidant can be one of sodium sulfite, vitamin C / E, sodium thiosulfate, and butylated p-hydroxyanisole; The filler in the coloring coating may be one or more of sucrose, corn starch, lactose, and microcrystalline cellulose; the colorant may be one or more of titanium dioxide and yellow / brown iron oxide; the binder may be one or more of povidone K30 / K90 and hypromellose; The solvent was purified water.

[0021] The preparation method comprises: (1) Compression of placebo tablet cores: Accurately weigh the prescription amount of the placebo tablet core and the excipients, place them in a suitable stainless steel powder mixer, and mix them to obtain a completely uniform powder for 10 to 15 minutes. Based on the theoretical tablet weight of 120 mg, control the tablet weight difference of ±3 mg to obtain the placebo tablet core; (2) Preparation of sirolimus solid dispersion: Add stabilizer polyethylene glycol and purified water to a beaker and stir with a stirrer. The stirring intensity is determined according to the amount of material to ensure that all materials can be stirred and suspended. The stirring time is until the excipients are dissolved. Add the prescribed amount of sirolimus to the solution and stir with a stirrer to prepare sirolimus slurry. Use a high-pressure homogenizer and set the parameters: operating speed 40 Hz, pressure 350 bar, homogenization time 5 min. Pump the sirolimus slurry in a circulation manner so that it passes through the high-pressure homogenizer and the circulation chamber, thereby forming a sirolimus solid dispersion. Take a sample of the sirolimus concentrated dispersion and measure the particle size using an optical particle size distribution analyzer (the mean value of the particle size distribution is required to be <400 nm); Detect the concentration of sirolimus (the concentration is required to be less than 40 mg / g); (3) Preparation and application of active filler coating solution: Use a stirrer to stir the solid dispersion. First, add an appropriate amount of purified water to the sirolimus solid dispersion. Add the antioxidant vitamin E, filler microcrystalline cellulose and binder povidone K30 while stirring. Stir for about 3 hours until a slurry with obvious homogeneity and no large excipient particles visible to the naked eye is obtained. Take a sample of the active filler coating solution and test its concentration (the concentration is required to be less than 200 mg / g); Calculate the target tablet weight gain based on the active filler suspension content; Place the placebo tablet cores in a coating pan of appropriate size, coat the tablet cores with sufficient active filler coating solution until the target tablet weight is reached, stop coating, start drying, set the drying parameters to 35°C and 30 minutes, and obtain active filler coated tablets; Confirm that the target mean tablet weight gain has been achieved, i.e., within the range of 95-110% of the placebo core weight, and if not, proceed with additional coating; (4) Preparation and application of colored coating liquid: Add purified water to a suitable container, stir with a stirrer, add filler, binder and colorant at the same time, and continue stirring for about 2 hours to obtain a uniform colored coating liquid suspension; The active filler coated tablets are placed in a coating pan of appropriate size, and sufficient color coating suspension is coated on the active filler coated tablets until the target tablet weight gain is reached, that is, the weight gain ratio can be 10-20%, preferably the color coating layer weight gain is 21.4 mg, the coating is stopped, and drying is started, and the drying parameters are set to 35° C. and 30 minutes to obtain sirolimus coated tablets; Confirm that the average target tablet weight gain has been achieved, and if not, proceed with additional coating; Example 2: Placebo core tablet + seal layer coating + active filler coating + color coating formulation (preferred)

[0022] In the sealing layer coating, the plasticizer can be one or more of citrate, phthalate, glycerin, and polyethylene glycol; the coating agent can be one or more of resin, gum arabic, shellac, and calcium sulfate; and the solvent is industrial alcohol.

[0023] The rest is the same as in Example 1.

[0024] The preparation method comprises: (1) Compressing placebo tablet cores: same as in Example 1; (2) Preparation and application of sealing layer coating solution: Dissolve the plasticizer glycerin in a 40-50°C industrial alcohol solution, add the coating agent resin to the alcohol hot solution containing the plasticizer prepared in the previous step, and stir until uniform to obtain a sealing layer coating solution; (3) Add the compressed placebo tablet cores into the coating pan, seal-coat each tablet with the target amount of coating solution, and dry the sealed tablets for at least 12 hours at a drying temperature of 25°C to obtain sealed coated tablets; the weight gain ratio of the sealed coated tablets relative to the placebo tablet cores is 15-20%.

[0025] (4) Preparation of sirolimus solid dispersion: Same as Example 1; the weight gain ratio of the active filler coated tablet to the seal coated tablet is 70-80%.

[0026] Preparation and application of active filler coating solution: The preparation of active filler coating solution is the same as in Example 1; the active filler coating solution is sprayed on the seal-coated tablets, and the operation is the same as in Example 1; (5) Preparation and application of colored coating solution: Same as Example 1. The weight gain ratio of the sirolimus coated tablets relative to the active filler coated tablets is 7-15%. Example 3

[0027] Placebo core tablet + inert filler coating + active filler coating + coloring coating formula

[0028] The filler in the inert filler can be one or more of sucrose, corn starch, lactose, and microcrystalline cellulose; the sunscreen can be one or more of titanium dioxide and calcium carbonate; the solvent is water; The rest is the same as in Example 1.

[0029] The preparation method comprises: (1) Compressing placebo tablet cores: same as in Example 1; (2) Preparation and application of inert filler coating solution: Heat purified water to 63-67°C; add the sunscreen titanium dioxide and filler sucrose while heating and stirring; continue stirring for about 30 minutes; cool to room temperature and keep stirring during the coating process; Place the placebo tablet cores in a coating pan and coat them with an inert filler until the average target tablet weight is reached to obtain inert filler coated tablets. The weight gain ratio of the inert filler coated tablets relative to the placebo tablet cores is 80-90%.

[0030] (3) Preparation of sirolimus solid dispersion: same as Example 1; (4) Preparation and application of active filler coating solution: The preparation of active filler coating solution is carried out in the same manner as in Example 1; the active filler coating solution is sprayed on inert filler tablets in the same manner as in Example 1; the weight gain ratio of the active filler coated tablets relative to the inert filler coated tablets is 45-55%.

[0031] (5) Preparation and application of colored coating solution: Same as Example 1. The weight gain ratio of the sirolimus coated tablets relative to the active filler coated tablets is 5-10%.

[0032] Results discussion and analysis: 1. Evaluation of melt similarity: The similarity factor (f2) is a parameter that measures the similarity of two dissolution curves. The calculation formula is as follows:

[0033] Where n is the number of sampling time points, Rt is the dissolution value of the reference sample (or sample before change) at time t, and Tt is the dissolution value of the test batch (sample after change) at time t.

[0034] The specific steps for determining the similarity factor are as follows: (1) Take 12 tablets (granules) of the test sample (after the change) and the reference sample (before the change) respectively, and measure their dissolution curves.

[0035] (2) Take the average dissolution value at each time point on the two curves and calculate the similarity factor (f2) according to the above formula.

[0036] (3) The closer the f2 value is to 100, the more similar the two curves are considered. Generally, when the f2 value is higher than 50, the two curves are considered similar and the test product (after the change) is equivalent to the reference product (before the change).

[0037]

[0038] Depend on Figure 1 As can be seen from the table above, the dissolution curve similarity factors of Example 2 and Example 3 with the reference preparation are relatively high, 84 and 73 respectively, while the dissolution curve similarity factor of Example 1 with the reference preparation is relatively low, 59, and the dissolution is relatively fast. From the data, it can be seen that the preparation method of the present invention can obtain a sample with a dissolution similar to that of the reference. On this basis, adding a sealing layer coating or an inert filler coating between the placebo tablet core and the active filler component coating can make the dissolution of the homemade sample consistent with the reference preparation. The dissolution curve of the present invention is better, and the solubility of sirolimus in the gastrointestinal tract can be improved by the preparation method of the present invention, thereby improving its oral bioavailability.

[0039] 2. Stability test: 2.1 Moisture

[0040] From the moisture stability data, it can be seen that the samples without sealing layer coating (Example 1 and Example 3) have a large increase in moisture during the stability placement process. The moisture content of the sample under accelerated conditions in Example 1 increased from 2.3% to 4.4% in 3 months, an increase of 91%, and has exceeded the moisture limit. The moisture content of the sample under accelerated conditions in Example 3 increased from 2.1% to 3.6% in 3 months, an increase of 71%, which is close to the moisture limit. The moisture content of the sample with sealing layer coating (Example 2) has almost no change, and the sample quality is consistent with the reference preparation. 2.2 Related substances

[0041] From the results of related substances, it can be seen that the samples without sealing layer coating (Example 1 and Example 3) had a large increase in single unknown degradation impurities during the stability placement process. The single unknown degradation impurity of the sample under accelerated conditions for 3 months in Example 1 increased from 0.086% to 0.21%, an increase of 144%, and exceeded the limit of single unknown degradation impurities. The single unknown degradation impurity of the sample under accelerated conditions for 3 months in Example 3 increased from 0.067% to 0.16%, an increase of 139%, which is close to the limit of single unknown degradation impurities. The single unknown degradation impurity of the sample with sealing layer coating (Example 2) increased slightly by 0.028%. The increase in single unknown degradation impurities of the reference preparation was 0.036%, which was higher than the increase in single unknown degradation impurities of the sample in Example 2. Example 2 is better than the reference preparation.

Claims

1. A sirolimus coated tablet, characterized in that: The sirolimus coated tablet comprises, from the inside to the outside, a placebo core, a sealing layer coating, an active filler coating and a coloring coating, wherein the placebo core comprises a diluent, a binder and a lubricant; the sealing layer coating comprises a plasticizer, a coating agent and a solvent; the active filler coating comprises sirolimus, a stabilizer, a solvent, a filler, a binder and an antioxidant; and the coloring coating comprises a filler, a colorant, a binder and a solvent.

2. The sirolimus coated tablet according to claim 1, characterized in that The mass ratio of placebo core, seal layer coating, active filler coating and coloring coating is: 5~6:1:4~6:

1.

3. The sirolimus coated tablet according to claim 1, characterized in that In the placebo tablet core, the diluent is one or more of starch, dextrin, lactose, and microcrystalline cellulose; the binder is one or more of povidone K30 / K90, hypromellose, and polyethylene glycol; the lubricant is one or more of magnesium stearate, talc, and silicon dioxide; In the sealing layer coating, the plasticizer is one or more of citrate, phthalate, glycerin, and polyethylene glycol; the coating agent is one or more of resin, gum arabic, shellac, and calcium sulfate; and the solvent is alcohol; In the active filler coating, the stabilizer is one or more of polyethylene glycol, castor oil, poloxamer, and Tween; the solvent is water; the filler is one or more of sucrose, corn starch, lactose, and microcrystalline cellulose; the binder is one or more of povidone K30 / K90 and hydroxypropyl methylcellulose; the antioxidant is one of sodium sulfite, vitamin C / E, sodium thiosulfate, and butylated p-hydroxyanisole; In the colored coating, the filler is one or more of sucrose, corn starch, lactose, and microcrystalline cellulose; the colorant is one or more of titanium dioxide and yellow / brown iron oxide; the binder is one or more of povidone K30 / K90 and hypromellose; and the solvent is water.

4. The method for preparing the sirolimus coated tablet according to claim 1, characterized in that: The preparation method comprises the following steps: mixing a diluent, a binder and a lubricant and then tableting to obtain a placebo tablet core; adding a coating agent to an alcohol solution containing a plasticizer, stirring evenly to obtain a sealing layer coating solution, applying a sealing layer coating to the placebo tablet core and drying to obtain a sealed coated tablet; After the stabilizer and the solvent are uniformly mixed, sirolimus is added, and the sirolimus slurry is obtained after stirring, and the sirolimus slurry is pumped in a circulation manner and passed through a high-pressure homogenizer and a circulation chamber to obtain a sirolimus solid dispersion; purified water is first added to the sirolimus solid dispersion, and an antioxidant, a filler and a binder are added while stirring to obtain an active filler coating liquid, and the active filler coating liquid is sprayed on the sealed coated tablets to obtain active filler coated tablets; The filler, colorant, binder and solvent are mixed uniformly to obtain a color coating liquid, and the color coating liquid is sprayed on the active filler coated tablet to obtain sirolimus coated tablets.

5. The method for preparing the sirolimus coated tablet according to claim 4, characterized in that: The particle size distribution mean of the sirolimus solid dispersion is controlled to be <400 nm.

6. The method for preparing the sirolimus coated tablet according to claim 4, characterized in that: Placebo cores were seal coated with a seal coat and dried for at least 12 hours at 25 ± 2 °C.

7. The method for preparing the sirolimus coated tablet according to claim 4, characterized in that: The temperature of the alcohol solution is 40-50°C.

8. The method for preparing the sirolimus coated tablet according to claim 4, characterized in that: In the sirolimus solid dispersion, the concentration of sirolimus is less than 40 mg / g.

9. The method for preparing the sirolimus coated tablet according to claim 4, characterized in that: The concentration of the active filler coating solution is less than 200 mg / g.

10. The method for preparing the sirolimus coated tablet according to claim 4, characterized in that: The weight gain of the active filler coated tablets relative to the placebo core tablets is 80-110%.

Citation Information

Cited By

  • Coating composition, coating pharmaceutical preparation prepared from coating composition and preparation method of coating pharmaceutical preparation

    CN120131578A

  • Sirolimus enteric microcapsule granule and preparation method thereof

    CN122097311A